Abstract Sex hormones may play a role in the determination of cardiovascular disease. Recently lipoprotein(a) (Lp[a]) has been recognized as a risk factor for coronary heart disease. Estrogens and anabolic steroids have been reported to alter Lp(a) levels, yet no data are available on the association between in vivo concentrations of sex hormones and Lp(a) concentrations. We examined the possible associations of sex hormone-binding globulin, total and free testosterone, estradiol, and dehydroepiandrosterone sulfate to Lp(a) concentrations in men in two population-based studies (San Antonio Heart Study [n=178] and a Finnish study on the association between insulin resistance and atherosclerosis [n=87]). In neither study were sex hormones significantly related to Lp(a) concentrations. In addition, Lp(a) was significantly related to apolipoprotein(a) molecular weight (which was measured in the Finnish study only). These results were unchanged when Lp(a) concentrations were adjusted for apolipoprotein(a) molecular weight (a strong correlate of Lp[a] concentrations). We conclude that in vivo concentrations of sex hormones are unlikely to be associated with Lp(a) concentrations in men. (Arterioscler Thromb. 1994;14:19-24.) Key Words • sex hormones • lipoprotein(a) S ex hormones may play a role in the determination of risk of cardiovascular disease. Indirect evidence for this concept is provided by the higher triglyceride and low-density lipoprotein cholesterol (LDL-C) and lower high-density lipoprotein cholesterol (HDL-C) levels in men than women.
S ex hormones may play a role in the determination
of risk of cardiovascular disease. Indirect evidence for this concept is provided by the higher triglyceride and low-density lipoprotein cholesterol (LDL-C) and lower high-density lipoprotein cholesterol (HDL-C) levels in men than women. 1 In vivo, sex hormones have been related to cardiovascular risk factors in men and women. 210 Interestingly, the association of testosterone with lipids and lipoproteins may be different in men than women. Increased levels of free testosterone and decreased levels of sex hormonebinding globulin (SHBG) are associated with atherogenic changes in lipid and lipoprotein profiles (especially increased triglyceride and decreased HDL-C concentrations) in premenopausal and postmenopausal women. 2 -5 However, increased testosterone concentrations in men have been associated with higher HDL-C levels in most 68 but not all 9 -10 studies.
Recently, lipoprotein(a) (Lp[a]) has been associated with increased coronary heart disease. 1115 The determinants of Lp(a) concentration have a major genetic component. 16 - 17 Since Lp(a) concentrations do not vary between men and women, 1820 it would be expected that sex hormones would not have a major effect on Lp(a) concentration. However, a number of observations do suggest a possible role for sex hormones in modulating Lp(a) concentrations. Lp(a) levels are higher in postmenopausal ' 21 Postmenopausal estrogen accompanied by progestagen therapy has been reported to lower Lp(a) concentrations. 22 - 23 Pharmacological intervention with anabolic steroids in men and women 24 and estrogen therapy in men with prostatic carcinoma 25 have been shown to reduce Lp(a) concentrations. Orchiectomy in men with prostatic cancer has led to increases in Lp(a) concentrations. 25 Lp(a) levels have been found to be higher in postpubertal than prepubertal subjects with insulin-dependent diabetes mellitus.
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To date, no study has examined the association of in vivo sex hormones and binding proteins with Lp(a) concentrations. In this report, we examine the influence of total and free testosterone, dehydroepiandrosterone sulfate, estradiol, and SHBG on plasma Lp(a) concentrations in men from two population-based studies in the United States and Finland. Since obesity, body fat distribution, and hyperinsulinemia may be associated with alterations in sex hormones, 25 -7 we have controlled for these factors. In addition, because genetic factors may have a major influence on Lp(a) concentration, 1617 we have also accounted for apolipoprotein(a) (apo[a]) phenotype effects on Lp(a) concentrations in the Finnish population.
Methods
San Antonio Heart Study
The San Antonio Heart Study is a population-based study of diabetes and cardiovascular disease in Mexican Americans and non-Hispanic whites. Between 1979 and 1982, 1288 Mexican Americans and 929 non-Hispanic white men and nonpregnant women, aged 25 to 64 years old when first examined, were randomly selected from three neighborhoods in San Antonio, Tex. Mexican Americans are defined as individuals whose ancestry and cultural traditions are derived from a Mexican national origin. 23 The response rate was 63.9%. A detailed description of the survey has been published. 29 The study was approved by the Institutional Review Board of the University of Texas Health Science Center at San Antonio, and all subjects gave informed consent. In October 1987, follow-up of the 1979 to 1982 cohort was begun to ascertain the incidence of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease. Vital status was ascertained for 97.8% of the originally enrolled subjects. The follow-up examination consisted of an initial home interview (completed by 96.9% of the surviving subjects) followed by a medical examination (which was attended by 82.9% of the subjects who completed the telephone interview). The overall response rate was 80.3% (0.969x0.829). A total of 969 Mexican Americans and 704 non-Hispanic whites attended the follow-up examination. Details of the follow-up study have been published. 30 The analyses in this report are based on 178 male subjects for whom fasting serum samples were available and who lived in a middle-income neighborhood (sixth census tracts of the follow-up study).
Anthropometric measurements (height, weight, and waist and hip circumferences) were done with the participant's wearing an examination gown after removal of his shoes and upper garments. 31 Waist circumference was measured at the level of the umbilicus and hip circumference at the level of the greater trochanter. The average of two readings was used as the measurement for each circumference. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared, and BMI was used as an index of overall adiposity. The ratio of waist-to-hip circumference (WHR) was used as a measure of upper body adiposity.
Blood samples were obtained after a 12-hour fast. Methods for determination of serum lipids and Iipoproteins have been described. 29 Glucose levels were measured by a glucose oxidase method, and insulin was measured with a commercial solid-phase radioimmunoassay (Diagnostic Products Corp, Los Angeles, Calif). After the fasting blood samples were obtained, a 75-g glucose equivalent load (Koladex or Orangedex; Custom Laboratories, Baltimore, Md) was administered orally. Blood specimens for plasma glucose and serum insulin concentrations were obtained 2 hours after the glucose load. Multiple aliquots of fasting serum specimens obtained at follow-up were saved as contingency samples and were frozen at -70°C. One aliquot was not thawed until the analyses for sex hormones and binding proteins were performed an average of 6 months later. Estradiol, total testosterone, and dehydroepiandrosterone sulfate (DHEA-SO 4 ) were measured with solid-phase commercial radioimmunoassays (Diagnostic Products Corp). Free testosterone was measured with a commercial double-antibody system (Diagnostic Products Corp). SHBG was measured by a commercial double-antibody system (Diagnostic Systems Laboratory, Webster, Tex). The intra-assay and interassay coefficients of variation, respectively, were 6.0% and 9.0% for SHBG, 4.1% and 6.0% for total testosterone, 5.9% and 7.2% for estradiol, and 5.8% and 7.9% for DHEA-SO 4 . The lower limit of sensitivity for the free testosterone assay is 0.15 pg/mL. In our laboratory, the intra-assay coefficient of variation for free testosterone is 5.0% and the interassay coefficient of variation is 7.0% for male specimens.
From a separate serum aliquot that was frozen at -70°C for an average of 12 months before assay, Lp(a) was measured by a monoclonal Lp(a) antibody technique (Terumo Medical Corp, Elkton, Md). The intra-assay and interassay coefficients of variation for Lp(a) were 4% and 8%, respectively. 32 In a recent report of this monoclonal antibody technique, no cross-reactivity with plasminogen, LDL-C, very-low-density lipoprotein cholesterol, or HDL-C was observed. 33 Diabetes was diagnosed according to the criteria of the World Health Organization (fasting plasma glucose >7.8 ramol/L and/or a 2-hour glucose >11.1 mmol/L). 34 Subjects with diabetes (n=40) have been excluded from the present analyses.
Finnish Insulin Resistance and Atherosclerosis Study
The subjects for this study were drawn from a larger study whose aim was to associate insulin resistance with asymptomatic atherosclerosis in middle-aged, healthy men. 35 These 87 men were originally selected from a population-based study designed to investigate previously unestablished risk factors for ischemic heart disease and carotid atherosclerosis.
3 * None of the subjects had any chronic disease, any drug treatment that could influence carbohydrate metabolism, any abnormality in an oral glucose tolerance test (impaired glucose tolerance or diabetes according to the criteria of the World Health Organization), 34 or hypertension (use of antihypertensive drugs or systolic/diastolic blood pressure > 160/95 mmHg). Furthermore, liver, kidney, and thyroid function tests were normal in every subject. Anthropometric measurements (height, weight, and waist and hip circumferences) were performed as in the San Antonio Heart Study.
Blood samples were obtained after a 12-hour fast for serum lipid, lipoprotein, glucose, and insulin concentrations. After the fasting samples were obtained, a 75-g glucose load was administered orally, and blood samples for plasma glucose and plasma insulin concentrations were obtained 1 and 2 hours after the glucose load. Blood glucose in the fasting state was measured by the glucose oxidase method. Plasma insulin was determined by radioimmunoassay (Phadeseph Insulin RIA 100; Pharmacia Diagnostics AB, Uppsala, Sweden). Serum lipid and lipoprotein levels were determined from fresh serum samples drawn after a 12-hour overnight fast. Lipoprotein fractionation was performed by ultracentrifugation and selective precipitation as described. 37 Cholesterol and triglyceride levels from whole sera and from lipoprotein fractions were assayed by automated enzymatic methods (Boehringer-Mannheim, Mannheim, FRG). 38 Sex hormones and Lp(a) were measured in sera (frozen at -70°C for an average of 25 months) in the laboratory of the San Antonio Heart Study using methods that were identical to those used in the San Antonio Heart Study.
Determination of Apo(a) Molecular Weight
Apo(a) isoform sizes were determined by immunochemical detection of apo(a) among serum proteins that were resolved by sodium dodecyl sulfate electrophoresis. 17 All but one sample had at least one detectable apo(a) isoform. The sizes of apo(a) bands were estimated by comparison with the mobilities of four apo(a) bands in a standard loaded gel on an immediately adjacent lane. The molecular weights of bands in the standard were based on mobilities relative to apo B and cross-linked phosphorylase b. 39 Size estimates represent results from an average of 3.7 different runs, and the average coefficient of variation was 1.7% (all were <4%). Apo(a) isoform size (molecular weight) is specified at the LPA locus, which also controls a large proportion of variation in Lp(a) level. 40 In fact, apo(a) size appears to be inversely related to Lp(a) level in several populations. 41 Therefore, in Table 3 we attempted to adjust Lp(a) levels for the contribution of size by including the molecular weight of the isoform (single-banded phenotypes) or the smaller isoform (double-banded phenotypes).
Apo(a) isoforms were also phenotyped into five size categories, with A having the largest molecular weights and E the smallest. The estimated average molecular weights of isoform categories for this study were 788 000, 695 000, and 598 000 for A, B, and C, respectively; the other two isoform categories (D and E) were observed in only four individuals. There was one null-phenotype individual in the study, which indicated that neither allelic product was detected in the serum sample. The presence of null-phenotype alleles means that a single-banded phenotype, such as A, can represent either the AA or AN genotype (where N is the null allele). An ANOVA (Table 4) phenotypes (ie, three or more individuals with that phenotype).
Statistical Methods
The following statistical tests (SAS) 42 were used: t tests (Table 1) , Pearson correlation coefficients (Tables 2 and 3),  ANOVA (Table 4) , and partial correlation analysis (Tables 2  and 3 ). Log transformations of Lp(a) and triglyceride concentrations were used to improve adherence to an assumed gaussian distribution for use with t tests (Table 1) , Pearson and partial correlations (Tables 2 and 3) , and ANOVA (Table 4 ). The analyses in this report were initially performed separately for Mexican Americans and non-Hispanic whites. Since relations between sex hormones and Lp(a) were similar in Mexican Americans and non-Hispanic whites (ie, slope of the correlation coefficient) (Table 2) •Adjusted for age, ethnicity, body mass index, walst-to-hlp ratio, fasting glucose, and fasting insulin. groups were pooled to simplify the presentation and improve statistical power. Table 1 shows clinical and metabolic characteristics of the study subjects. In San Antonio there was no ethnic difference (Mexican Americans versus non-Hispanic whites) for any variable. Mexican Americans had a mean Lp(a) concentration of 11.8 ±1.5 mg/dL compared with 16.4±1.9 mg/dL in non-Hispanic whites. In Finland the mean Lp(a) concentration was 16.5 ±0.2 mg/dL. Table 2 shows correlations between sex hormones and Lp(a) concentrations in the San Antonio Heart Study. Sex hormones were not significantly correlated with Lp(a) in either univariate or multivariate analysis. Table 3 shows correlations between sex hormones, Lp(a) concentrations, and apo(a) molecular weights in the Finnish study. Neither Lp(a) concentration nor apo(a) size was significantly related to any of the sex hormones. Lp(a) concentration was significantly related to apo(a) molecular weight (r=-.600, / > <.001). After adjustment for age, BMI, WHR, fasting glucose, and fasting insulin, Lp(a) concentrations were not significantly related to any of the sex hormones (data not shown). Table 4 shows apo(a) molecular weights and concentrations of sex hormones and Lp(a) by apo(a) letter phenotype in the Finnish study. Molecular weights of apo(a) and Lp(a) concentrations were significantly related to apo(a) letter phenotype (F<.001). However, none of the sex hormones was significantly related to apo(a) phenotype.
Results
Discussion
We have shown in this report that sex hormone concentrations are not related to Lp(a) concentrations in two population-based studies. Since the lack of association between Lp(a) concentrations and sex hormones occurs in Caucasian populations in different parts of the world as well as in Mexican Americans (a population with increased Native American admixture), these results are likely to be generalizable. In addition, the number of subjects in these samples was large. The lack of association between Lp(a) and sex hormones is not affected by adjustment for a number of factors that are known to affect concentrations of sex hormones, such as obesity, 43 ' 44 body fat distribution, 4344 and insulin and glucose concentrations. 43 -45 ' 46 Genetic factors are a major determinant of Lp(a) concentration. 1617 The apo(a) gene (LPA gene) may account for >90% of the variation in Lp(a) concentration. 40 Thus, apo(a) phenotype may have major influences on the association of environmental factors (such as sex hormones) with Lp(a) concentration. As observed by others, there was a strong inverse correlation between apo(a) molecular weight and Lp(a) concentration in this study. However, adjusting Lp(a) concentration for apo(a) phenotype did not alter the lack of association between Lp(a) concentrations and sex hor- Lp(a) Indicates lipoprotein(a); Apo(a), apolipoprotein(a); SHBG, sex hormone-binding globulin; and DHEA-SO 4 , dehydroepiandrosterone sutfate. One subject had BE, 2 subjects had AE, 1 subject had AD, and 1 subject had a null phenotype. These subjects were excluded from this analysis. Probability values were calculated by ANOVA.
*Three subjects had an AA pattern (pseudohomozygoslty).
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The lack of association between in vivo sex hormones and Lp(a) concentrations contrasts with the effects of estrogen or anabolic steroid treatment on Lp(a) concentration. 2223 The observation that both exogenous estrogen and anabolic steroids decrease Lp(a) levels suggests that the effects of these hormones are related to initial effects on liver metabolism. The major source of Lp(a) variation in normal subjects is due to differences in Lp(a) synthesis in the liver. 47 ' 48 Differences in the effect of exogenous testosterone and anabolic steroid administration on HDL concentrations have also been reported. Anabolic steroids have been associated with decreased HDL-C and increased LDL-C concentrations, 4951 whereas testosterone administration has little effect on lipoproteins. 51 -52 However, these differences may be partially due to different routes of administration, since anabolic steroids are usually given orally and testosterone is usually administered by intramuscular injection. One explanation for the differences between oral androgens and intramuscular testosterone on HDL-C levels is that testosterone readily aromatizes to 17-/3-estradiol, whereas oral androgens do not form potent estrogens. 53 Administration of testosterone enanthate with testolactone (which inhibits aromatization of testosterone to 17-/3-estradiol) leads to increases in hepatic trigh/ceride lipase and decreases in HDL-C. 52 The latter observation suggests that aromatization to estradiol is responsible for the testosterone effect, which does not occur with anabolic steroid use. An intramuscular testosterone model may thus provide a better model for the effect of in vivo sex hormones on Lp(a) concentrations.
In conclusion, we have demonstrated a lack of effect of sex hormones on Lp(a) concentrations in men. These results were not affected by adjustment for confounding variables, such as obesity and insulin concentrations, nor were they affected by adjustment for apo(a) molecular weight. These studies should be repeated in women. The paradox between the lowering of Lp(a) concentrations by estrogen or anabolic steroid treatment and the current findings that show no association of in vivo sex hormones with Lp(a) concentrations might be partially resolved by examining the effect of intramuscular testosterone. Perhaps intramuscular testosterone does not affect Lp(a) concentrations. Measurement of apo(a) phenotype would also be useful, since the effect of sex hormones might differ by phenotype.
